Combination Long-Acting β-Agonists and Inhaled Corticosteroids Compared With Long-Acting β-Agonists Alone in Older Adults With Chronic Obstructive Pulmonary Disease
Open Access
- 17 September 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 312 (11) , 1114-1121
Abstract
Chronic obstructive pulmonary disease (COPD) affects 5% to 22% of adults older than 40 years, has a lifetime risk of more than 25%, and is the third leading cause of death worldwide.1-3Keywords
This publication has 20 references indexed in Scilit:
- A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims dataBMC Pulmonary Medicine, 2014
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2012
- Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population studyThe Lancet, 2011
- Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studiesThorax, 2011
- Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary DiseaseAnnals of Internal Medicine, 2008
- Global burden of COPD: risk factors, prevalence, and future trendsThe Lancet, 2007
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Performance of the ACG Case-Mix System in Two Canadian ProvincesMedical Care, 2001